US OptionsDetailed Quotes
ATHA250117C2500
- 0.05
- 0.000.00%
15min DelayTrading Dec 10 15:18 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume577 Open Interest2.50Strike Price0.00Turnover472.25%IV372.22%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2258Delta0.4908Gamma10.80Leverage Ratio-0.0041Theta0.0000Rho2.44Eff Leverage0.0004Vega
Athira Stock Discussion
Sign in to post a comment
$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
51
25
6
$Athira (ATHA.US)$
This is their balance sheet as of SEP 2024, in this it shows stock holders equity 57Mil, which is now down to 25M(Market cap), so the liability is 25+28=53Mil which is still less than the cash they hold 69Mil...
This is their balance sheet as of SEP 2024, in this it shows stock holders equity 57Mil, which is now down to 25M(Market cap), so the liability is 25+28=53Mil which is still less than the cash they hold 69Mil...
1
$Athira (ATHA.US)$
someone new something 👀
someone new something 👀
3
2
$Athira (ATHA.US)$
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
Friday, 6th December at 5:30 pm
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highli...
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
Friday, 6th December at 5:30 pm
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highli...
1
2
$Athira (ATHA.US)$ Why is it going up so slowly? Is it we are waiting for a bigger news?
1
1
$Athira (ATHA.US)$ no downside they closed down that failing company months ago false news been working out of their new lab for almost a year now and with AI about to cut workforce cost we will see more profits 📈 😉
3
3
No comment yet
凑仔公阿当 : I hope so